...
首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.
【24h】

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.

机译:美国国立卫生研究院关于慢性移植物抗宿主病临床试验标准的共识研究项目:VI。临床试验工作组设计报告。

获取原文
获取原文并翻译 | 示例
           

摘要

The complexity of chronic graft-versus-host disease (GVHD) and the lack of established research methods have made it difficult to design, conduct, and analyze clinical trials involving subjects with this disease, even when promising treatment options are available. This consensus document was developed to offer an approach for overcoming these obstacles. Clinical trials in chronic GVHD should adhere to principles of good trial design and practice. Inclusion and exclusion criteria should allow as many subjects to participate as possible without compromising the interpretation of results. Pre-enrollment assessment of chronic GVHD characteristics should be standardized. The protocol should provide clear guidance about administration of study medication and other interventions. Methods of assessing response should be defined and validated in advance. Efficacy endpoints should be selected to reflect clinical benefit. Expert biostatistical support is needed to ensure the validity and reliability of trial results. The use of consistent standards in clinical trial designs to evaluate agents that have activity in pathogenic pathways could facilitate advances in the treatment of chronic GVHD.
机译:慢性移植物抗宿主病(GVHD)的复杂性以及缺乏成熟的研究方法,使得即使有可行的治疗方案,也难以设计,进行和分析涉及该病受试者的临床试验。制定这份共识文件旨在提供一种克服这些障碍的方法。慢性GVHD的临床试验应遵循良好试验设计和实践的原则。纳入和排除标准应允许尽可能多的受试者参加,而不会影响结果的解释。慢性GVHD特征的入组前评估应标准化。该方案应提供有关研究药物和其他干预措施的明确指导。评估响应的方法应事先定义和验证。应选择疗效终点以反映临床获益。需要专家的生物统计支持以确保试验结果的有效性和可靠性。在临床试验设计中使用一致的标准来评估在致病途径中具有活性的药物可以促进慢性GVHD的治疗进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号